269 related articles for article (PubMed ID: 6107263)
1. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.
van Hees PA; Bakker JH; van Tongeren JH
Gut; 1980 Jul; 21(7):632-5. PubMed ID: 6107263
[TBL] [Abstract][Full Text] [Related]
2. Active therapeutic moiety of sulphasalazine.
van Hees PA; van Tongeren JH; Bakker JH; van Lier HJ
Lancet; 1978 Feb; 1(8058):277. PubMed ID: 74700
[No Abstract] [Full Text] [Related]
3. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
[TBL] [Abstract][Full Text] [Related]
4. Which component of sulphasalazine is active in rheumatoid arthritis?
Pullar T; Hunter JA; Capell HA
Br Med J (Clin Res Ed); 1985 May; 290(6481):1535-8. PubMed ID: 2860942
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
Klotz U; Maier K; Fischer C; Heinkel K
N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
[TBL] [Abstract][Full Text] [Related]
6. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis.
van Hogezand RA; van Hees PA; van Gorp JP; van Lier HJ; Bakker JH; Wesseling P; van Haelst UJ; van Tongeren JH
Aliment Pharmacol Ther; 1988 Feb; 2(1):33-40. PubMed ID: 2979230
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents (sulphapyridine and 5-aminosalicylic acid) in rats.
Garg GP; Cho CH; Ogle CW
Pharmacology; 1990; 40(6):318-24. PubMed ID: 1978355
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.
Williams CN; Haber G; Aquino JA
Dig Dis Sci; 1987 Dec; 32(12 Suppl):71S-75S. PubMed ID: 3319461
[TBL] [Abstract][Full Text] [Related]
9. An experiment to determine the active therapeutic moiety of sulphasalazine.
Azad Khan AK; Piris J; Truelove SC
Lancet; 1977 Oct; 2(8044):892-5. PubMed ID: 72239
[TBL] [Abstract][Full Text] [Related]
10. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial.
D'Arienzo A; Panarese A; D'Armiento FP; Lancia C; Quattrone P; Giannattasio F; Boscaino A; Mazzacca G
Am J Gastroenterol; 1990 Sep; 85(9):1079-82. PubMed ID: 2202199
[TBL] [Abstract][Full Text] [Related]
11. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
Bird HA
Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
[TBL] [Abstract][Full Text] [Related]
12. [Effect of 5-aminosalicylic acid as a constituent of sulfasalazine in the treatment of chronic polyarthritis].
Wörth WD; Müller W
Z Rheumatol; 1986; 45(2):79-82. PubMed ID: 2873695
[TBL] [Abstract][Full Text] [Related]
13. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis.
Neumann VC; Taggart AJ; Le Gallez P; Astbury C; Hill J; Bird HA
J Rheumatol; 1986 Apr; 13(2):285-7. PubMed ID: 2873245
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.
Ewe K; Eckardt V; Kanzler G
Scand J Gastroenterol Suppl; 1988; 148():70-5. PubMed ID: 2906479
[TBL] [Abstract][Full Text] [Related]
15. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.
Campieri M; De Franchis R; Bianchi Porro G; Ranzi T; Brunetti G; Barbara L
Scand J Gastroenterol; 1990 Jul; 25(7):663-8. PubMed ID: 2204103
[TBL] [Abstract][Full Text] [Related]
16. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
18. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
Ireland A; Mason CH; Jewell DP
Gut; 1988 Jun; 29(6):835-7. PubMed ID: 2898422
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
Rao SS; Cann PA; Holdsworth CD
Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
[TBL] [Abstract][Full Text] [Related]
20. [5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial].
Ngô Y; Rambaud JC
Gastroenterol Clin Biol; 1992; 16(6-7):558-63. PubMed ID: 1526418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
